Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05416203 · ClinicalTrials.gov registry record · NA

BEAST: A Pilot Trial

A NA study of Functional Impairment and Anxiety Sensitivity, sponsored by VA Office of Research and Development.

Completed
Registry status
NA
Development phase
15
Enrollment target
1
Study location

NCT05416203: Completed NA study of Functional Impairment and Anxiety Sensitivity, sponsored by VA Office of Research and Development.

NCT05416203 is a NA study of Functional Impairment and Anxiety Sensitivity that has completed, run by VA Office of Research and Development. The registered enrollment target is 15 participants, below the 3,806-participant average among 3 other Functional Impairment trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05416203, a NA study of Functional Impairment and Anxiety Sensitivity, has completed, sponsored by VA Office of Research and Development.

COMPLETED
Registry status
NA
Development phase
15 participants
Enrollment target
1
Study location

Study Summary

This pilot study trial will test the acceptability, feasibility, and usability of a brief enhanced anxiety sensitivity treatment to reduce anxiety sensitivity and functional impairment in Veterans.

Primary Outcome

Anxiety sensitivity will be measured via the Anxiety Sensitivity Index-3, an 18-item self-report measure assessing fear of negative consequences of anxiety-related symptoms. Scores range from 0 to 72 with higher scores indicating worse anxiety sensitivity.

Interventions

  • BEHAVIORAL Brief Enhanced Anxiety Sensitivity Treatment

Study Locations (1)

New York

  • VA Finger Lakes Healthcare System, Canandaigua, NY - Canandaigua

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2022-09-01
Est. Completion 2024-08-30
Phase NA
VA Office of Research and Development

1,668 total trials

What the finished NCT05416203 record still lists

NCT05416203 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 3,806-participant average among 3 other Functional Impairment trials with a reported enrollment target (100% lower).

The record links to 2 conditions, with Functional Impairment appearing as the primary indexed condition, and to 1 intervention - of which Brief Enhanced Anxiety Sensitivity Treatment is the first listed.

NCT05416203 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT05416203 about?

NCT05416203 is a clinical study titled "BEAST: A Pilot Trial". This pilot study trial will test the acceptability, feasibility, and usability of a brief enhanced anxiety sensitivity treatment to reduce anxiety sensitivity and functional impairment in Veterans.

What is the current status of trial NCT05416203?

This trial is currently completed. It is a NA study. The enrollment target is 15 participants. The study started on 2022-09-01. Estimated completion is 2024-08-30.

What conditions does trial NCT05416203 study?

This clinical trial studies the following conditions: Functional Impairment, Anxiety Sensitivity.

What interventions are being tested in trial NCT05416203?

The interventions under investigation include: Brief Enhanced Anxiety Sensitivity Treatment (BEHAVIORAL).

Who is sponsoring clinical trial NCT05416203?

This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05416203 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Functional Impairment

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01889381 · 15 participants · Phase 2

    Human Craniomaxillofacial Allotransplantation

  • NCT02530073 · 15 participants · NA

    Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH

  • NCT02535936 · 15 participants · NA

    Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy

  • NCT02918474 · 15 participants · NA

    Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05416203, the US trial registry maintained by the National Library of Medicine. NCT05416203 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.